Lung cancer remains one of China’s greatest cancer burdens. In the past, a diagnosis was often associated with advanced disease and limited options. Today, low-dose CT screening, molecular testing, minimally invasive surgery, targeted therapy, immunotherapy, and better supportive care are allowing some patients to live longer and manage lung cancer over time.
“Chronic disease management” does not mean that lung cancer has become harmless or that follow-up can be relaxed. It means building a continuous, individualized plan around precise diagnosis, timely treatment, treatment-safety monitoring, rehabilitation, and coordinated care across thoracic surgery, medical oncology, radiation oncology, pathology, radiology, and respiratory medicine.
China’s Lung Cancer Burden: High Incidence, High Mortality
Lung cancer ranks among the leading cancers in China for both incidence and mortality. Smoking remains a major risk factor, but lung cancer also affects people who have never smoked. Age, secondhand smoke, environmental and occupational exposure, family history, and previous lung disease may all contribute to risk.
The proportion of lung adenocarcinoma has increased, including among women and never-smokers. Early disease may cause no obvious symptoms. A persistent cough, blood in sputum, chest pain, shortness of breath, hoarseness, or unexplained weight loss warrants medical attention, but high-risk individuals should not wait for symptoms before discussing screening.
For a broader overview of diagnosis, staging, treatment, and care in Shanghai, read our complete lung cancer guide for international patients.
Precision Classification: More Than Confirming “Lung Cancer”
Lung cancer is not a single disease. Pathology and clinical staging remain the foundation of treatment planning. For appropriate patients with non-small cell lung cancer, biomarker testing can identify changes involving EGFR, ALK, ROS1, and other clinically relevant genes. Depending on the disease stage, pathology, sample quality, and local medical guidance, physicians may also assess KRAS, BRAF, MET, RET, NTRK, HER2, and PD-L1.
The testing strategy should be selected by the oncology team. If tissue is insufficient, a repeat biopsy or liquid biopsy may be discussed, but a blood test cannot replace tissue pathology in every situation. Patients should not purchase targeted drugs based on a single test result without specialist interpretation.
At Shanghai Pulmonary Hospital, the oncology teams led by Prof. Zhou Caicun and Prof. Su Chunxia have contributed extensively to precision lung cancer care and clinical research. Learn more about Prof. Zhou Caicun’s clinical focus in lung cancer precision medicine.
From Targeted Therapy to Immunotherapy
For patients with an actionable driver alteration, targeted therapy may become a central part of treatment. In EGFR-mutated lung cancer, third-generation tyrosine kinase inhibitors have improved disease control for selected patients and expanded options for managing central nervous system involvement. Resistance can still develop, making scheduled imaging, symptom review, laboratory monitoring, and, when appropriate, repeat molecular testing essential.
For patients without a suitable target, or those better suited to another approach, immune checkpoint inhibitors may be used alone or with chemotherapy and other treatments. The decision depends on pathology, stage, PD-L1 expression, molecular results, tumor burden, general health, other medical conditions, and previous treatment.
Immunotherapy can also cause immune-related side effects, including pneumonitis, thyroid dysfunction, hepatitis, and colitis. New cough, shortness of breath, fever, diarrhea, rash, or severe fatigue should be reported promptly. Our Shanghai lung cancer and advanced oncology treatment guide provides further background.
Why Shanghai’s Multidisciplinary Teams Matter
Shanghai brings together major specialist centers and experienced lung cancer teams. Shanghai Pulmonary Hospital has played an active role in clinical research, professional collaboration, and the development of standardized non-small cell lung cancer care in China. Its medical oncology teams focus on systemic treatment and long-term management, while thoracic surgeons, including the team led by Prof. Zhu Yuming, evaluate surgery for early-stage and selected locally advanced cases.
The key is not simply finding one famous doctor. The goal is to place complete medical information in front of the right specialists at the right time. Resectability, preoperative treatment, pathology review, molecular testing, radiation timing, and the management of brain or bone metastases may all require multidisciplinary discussion.
Patients considering surgery can also explore our lung cancer thoracic surgery feature.
Earlier Detection: Low-Dose CT and Scientific Lung Nodule Follow-Up
Low-dose CT is an important screening tool for people at elevated risk, but eligibility, starting age, and screening frequency should be determined with a physician based on age, smoking history, occupational exposure, family history, and previous lung disease. A standard chest X-ray is not equivalent to low-dose CT screening.
A lung nodule does not automatically mean lung cancer. Doctors assess its size, density, border, location, growth pattern, and changes compared with previous scans. A practical pathway may include:
- Collecting all previous chest CT images, not only written reports;
- Having a chest radiologist or lung nodule specialist compare changes over time;
- Selecting an appropriate CT interval or further testing based on risk;
- Discussing high-risk nodules with thoracic surgery, respiratory medicine, radiology, and oncology specialists;
- Avoiding unnecessary procedures for low-risk nodules while following the recommended schedule.
For more detail, see our guide to lung nodule diagnosis and individualized lung cancer treatment in Shanghai.
From One-Time Treatment to Long-Term Health Management
Long-term lung cancer management extends beyond anticancer treatment. A workable plan often includes:
- Disease monitoring: CT, MRI, laboratory tests, and other assessments at intervals defined by the treating team;
- Safety monitoring: documenting rash, diarrhea, breathing changes, fever, pain, appetite, weight, and other treatment-related symptoms;
- Nutrition and physical function: maintaining adequate protein and energy intake and using gradual walking, breathing exercises, or rehabilitation when medically appropriate;
- Smoking cessation and comorbidity care: managing COPD, cardiovascular disease, diabetes, and other conditions alongside cancer care;
- Psychological and family support: addressing sleep, anxiety, caregiver strain, and return-to-work concerns;
- Medical record continuity: keeping pathology, molecular reports, original imaging files, medication doses, and adverse-event records organized.
Stable disease does not mean follow-up should stop. The schedule and content of monitoring must remain individualized and should be adjusted by the treating physicians.
How CMCS Supports International Patients in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize their records, identify appropriate specialists in Shanghai, and coordinate communication before, during, and after medical visits.
Depending on the case, CMCS can assist with:
- Organizing the medical history, pathology, molecular reports, and original CT, PET-CT, or MRI files;
- Coordinating evaluation by medical oncology, thoracic surgery, radiation oncology, or a multidisciplinary team;
- Preparing a concise bilingual case summary and appointment question list;
- Supporting appointment planning, travel preparation, on-site communication, and examination scheduling;
- Organizing treatment instructions, follow-up milestones, and side-effect monitoring points;
- Facilitating necessary communication with family members after receiving the patient’s authorization.
Remote record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent medical records before case coordination. CMCS can usually address approximately three to five core questions during initial screening. If specific medical coordination is needed, the service scope and applicable fee will be explained before work begins.
Conclusion: Making Every Treatment Step Support a Longer, More Stable Life
Lung cancer care is moving from one-size-fits-all treatment toward precision classification and long-term management. Early-stage patients may pursue curative treatment and structured recurrence surveillance. Patients with advanced disease may achieve longer disease control through targeted therapy, immunotherapy, chemotherapy, radiation, surgery, or other local treatments selected for their situation.
When thoracic surgery, medical oncology, radiation oncology, diagnostics, rehabilitation, and supportive care work together, “living with lung cancer” becomes a practical care strategy rather than an abstract idea.
Contact CMCS
For help organizing lung cancer records, connecting with appropriate specialists in Shanghai, or planning a medical visit, contact us:
- Website: www.medicalsh.com
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
You may also submit your information through our contact page.
Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment advice. Screening, testing, medication, surgery, and follow-up plans must be determined by qualified physicians based on the patient’s complete medical information.
0件のコメント